Kamada Ltd. announced the appointment of Michal Ayalon, Ph.D., as Vice President of Research and Development. Dr. Ayalon has nearly 20 years of experience in drug discovery and drug development, including non-clinical and clinical development, manufacturing and control, regulatory, and project management. She will oversee all of Kamada's R&D and IP activities, and report directly to Amir London, Kamada's Chief Executive Officer. Dr. Ayalon will succeed Liliana Bar, Ph.D. who has served as Kamada's VP R&D since 2012 and is retiring next month. Prior to joining Kamada, Dr. Ayalon served as Head of R&D at 89bio Ltd., where she led the overall development strategy of the company and managed all R&D functions, including medical, clinical, pre-clinical, CMC, regulatory, and project management.